The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $62.36

Today's change-0.79 -1.25%
Updated January 23 4:10 PM -5GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $62.36

Today's change-0.79 -1.25%
Updated January 23 4:10 PM -5GMT. Delayed by at least 15 minutes.

Spdr S&P Biotech Etf crosses below 125-day moving average

Spdr S&P Biotech Etf closed lower Monday, dropping (U.S.)$0.79 or 1.25% to (U.S.)$62.36 and crossing below its 125-day moving average. Shares have lost 4.06% for the last five days, but have gained 12.75% over the last 52 weeks. This security has underperformed the S&P 500 by 6.04% during the last year.

Key company metrics

  • Open(U.S.) $63.08
  • Previous close(U.S.) $63.15
  • High(U.S.) $63.43
  • Low(U.S.) $61.97
  • Bid / Ask(U.S.) $62.40 / (U.S.) $62.48
  • YTD % change+5.36%
  • Volume3,977,121
  • Average volume (10-day)6,842,683
  • Average volume (1-month)5,985,397
  • Average volume (3-month)6,643,909
  • 52-week range(U.S.) $44.16 to (U.S.) $69.21
  • Beta1.57
  • Trailing P/E3.42×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.30
  • Dividend yield0.48%
  • Trailing EPS(U.S.) $18.23
Updated January 23 4:10 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,202.84%

Based on its net profit margin of 2,202.84%, Spdr S&P Biotech Etf is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.44%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q4/2014Q2/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Jun 30, 201406/30/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013
Revenue81032
Total other revenue--------
Total revenue81032
Gross profit--------
Total cost of revenue--------
Total operating expense2221
Selling / general / administrative2221
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income6811
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax262141200125
Income after tax262141200125
Income tax, total--000
Net income262141200125
Total adjustments to net income--------
Net income before extra. items262141200125
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items262141200125
Inc. avail. to common incl. extra. items262141200125
Diluted net income262141200125
Dilution adjustment--------
Diluted weighted average shares23202327
Diluted EPS excluding extraordinary itemsvalue per share11.217.028.674.61
Dividends per sharevalue per share0.350.310.040.03
Diluted normalized EPSvalue per share11.217.028.674.61